Nov 16, 2016

 

The University of Pittsburgh Drug Discovery Institute (DDI) is one among three institutes in the country to be awarded a grant to establish a new Tissue Chip Testing Center (TCTC). The grant, led by Dr. Mark Schurdak, Ph.D., associate professor of computational and systems biology at Pitt’s School of Medicine and Director of Operations of the Drug Discovery Institute, was awarded under the National Institutes of Health (NIH) tissue chip initiative. 

More


Aug 1, 2016
Dr. Lansing Taylor was awarded a grant entitled "Creating models of rare childhood liver diseases using human liver-on-a-chip" by the NIH-National Center for Advancing Translational Sciences.

Jul 1, 2016

Abstract

We describe a comprehensive, unbiased, integrated, and iterative quantitative systems pharmacology (QSP)–driven drug discovery and development strategy and platform that we have implemented at the University of Pittsburgh Drug Discovery Institute.

more


Jun 1, 2016
Dr. Albert Gough has received funding under an SBIR entitled "Development and Evaluation of a high through IPS Hepatotoxicity Screening Platform"

May 4, 2016

Dr. Lansing Taylor receives NIH funding for a project entitled "Informatics Tools for Tumor Heterogeneity in Multiplexed Fluorescence Images"


Apr 1, 2016
Dr. Andreas Vogt receives NIH funding with Dartmouth College for a project entitled "HTS for Dab2 Inhibitors as Stablizers of CFTR"

Mar 1, 2016

Abstract

Heterogeneity is well recognized as a common property of cellular systems that impacts biomedical research and the development of therapeutics and diagnostics. We demonstrate the use of the Kolmogorov–Smirnov statistic as a metric for monitoring the reproducibility of heterogeneity in an SAR screen, describe a workflow for quality control in heterogeneity analysis.

more


Jul 24, 2015

Abstract

This paper describes the development and characterization of a microphysiology platform for drug safety and efficacy in liver models of disease that includes a human, 3D, microfluidic, four-cell, sequentially layered, self-assembly liver model (SQL-SAL); fluorescent protein biosensors for mechanistic readouts; as well as a microphysiology system database (MPS-Db) to manage, analyze, and model data.

more


Mar 17, 2015

January 2015 - “ Alan Waggoner joins UPDDI as Group Leader Novel Biosensors”

More

 


Oct 12, 2014

 “One of the greatest challenges in biomedical research, drug discovery and diagnostics is understanding how seemingly identical cells can respond differently to perturbagens including drugs for disease treatment. To address this important issue we sought to define a method that could be readily implemented to identify, quantify and characterize heterogeneity in cellular and small organism assays to guide decisions during drug discovery and experimental cell/tissue profiling.” 

More


Aug 28, 2014

QSP-PM Workshop (November 19 and 20, 2013)

Quantitative Systems Pharmacology (QSP) for Personalized Medicine (PM)

Program

Report

 


Feb 10, 2014

University of Pittsburgh Announces the Creation of a Program to Create Therapeutics and Diagnostics for Metastatic Breast Cancer Based on Quantitative Systems Pharmacology (QSP) for Personalized Medicine

More


Feb 10, 2014

University of Pittsburgh Announces the Creation of a Program to Develop Therapeutics for Huntington’s Disease based on Quantitative Systems Pharmacology (QSP)

More


Oct 2, 2013

Nathan Yates joins the UPDDI as Chemical Proteomics group leader

More


Apr 22, 2013

Dr. Jeremy Berg is named as an Associate Director of the University of Pittsburgh Drug Discovery Institute

More


Apr 17, 2013

The pharmaceutical industry has experienced a decade of turbulence driven by the ‘patent cliff’ as major revenue generators are lost to generic status, coupled to the absence of a sustainable pipeline of drug candidates in development that have a good chance of being approved and launched1,2. It is generally agreed that the lowest hanging drug discovery ‘fruit’ has been harvested and the industry is addressing diseases that are more complex.

More


Jan 24, 2013

PITTSBURGH, Dec. 1 – Researchers at the University of Pittsburgh Schools of the Health Sciences and Magee- Womens Research Institute (MWRI) have been recently awarded four grants totaling nearly $11.5 million from the Bill & Melinda Gates Foundation.

 More


Oct 16, 2012

PITTSBURGH, Oct. 5, 2012 – Three investigators leading projects in cancer and one in HIV/AIDS are the first to receive awards from a fund established by the University of Pittsburgh, UPMC and Johnson & Johnson Corporate Office of Science and Technology (COSAT) to support promising translational research. More


Jul 31, 2012

PITTSBURGH, Date – Researchers at the University of Pittsburgh School of Medicine have been awarded federal grants to create micro-models of the liver and the arthritic joint as part of a national effort to build 3-D chips of cells and tissues that could provide a more rapid and accurate method of predicting toxicity of experimental therapies, as well as foster greater understanding of myriad diseases.

More...


Jun 19, 2012

Merkel cell polyomavirus (MCV) causes ~80% of primary and metastatic Merkel cell carcinomas (MCCs). By comparing digital transcriptome subtraction deep-sequencing profiles, we found that transcripts of the cellular survivin oncoprotein [BIRC5a (baculoviral inhibitor of apoptosis repeat-containing 5)] were up-regulated sevenfold in virus-positive
compared to virus-negative MCC tumors.

More...


Mar 2, 2012

PITTSBURGH, March 1 – The University of Pittsburgh and UPMC have entered into a partnership with Johnson & Johnson Corporate Office of Science and Technology (COSAT) to support translational research, which transforms lab findings into usable products and services, by jointly allocating research monies to university faculty from a mutually established fund. 

More...


Mar 2, 2012

Sitting atop the University of Pittsburgh’s Biomedical Science Tower 3 (BST3), researchers in Pitt’s Drug Discovery Institute (DDI) are searching for new methods to alleviate suffering caused by a variety of diseases. Their research includes studying the delicate protein interactions involved with cancer, designing new drug compounds, and developing automated technologies to enhance existing research methods. Their interests are diverse, yet their mission is the same—to advance global heath.

More...


Feb 28, 2012

Zebra fish are a valuable model. They share 70 to 80 percent of their genetic makeup with humans, and they develop many organs within 24 hours of fertilization.

More...